Literature DB >> 30359156

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Matthew S Davids1, Gottfried von Keudell1, Craig A Portell1, Jonathon B Cohen1, David C Fisher1, Francine Foss1, Andrew W Roberts1, John F Seymour1, Rod A Humerickhouse1, Constantine S Tam1.   

Abstract

Entities:  

Year:  2018        PMID： 30359156     DOI： 10.1200/JCO.18.00359

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.

Authors:  Alberto Fabbri; Emanuele Cencini; Angela Giovanna Congiu; Maurizio Miglino; Luigi Rigacci; Monica Bocchia
Journal:  Am J Blood Res       Date:  2020-12-15

Review 2.  What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?

Authors:  Kerstin Brinkmann; Ashley P Ng; Carolyn A de Graaf; Andreas Strasser
Journal:  Cell Death Differ       Date:  2022-04-06       Impact factor: 12.067

Review 3.  Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.

Authors:  Thomas E Lew; John F Seymour
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

Review 4.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

Review 5.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

6.  Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

Authors:  Peter Hillmen; Andy C Rawstron; Kristian Brock; Samuel Muñoz-Vicente; Francesca J Yates; Rebecca Bishop; Rebecca Boucher; Donald MacDonald; Christopher Fegan; Alison McCaig; Anna Schuh; Andrew Pettitt; John G Gribben; Piers E M Patten; Stephen Devereux; Adrian Bloor; Christopher P Fox; Francesco Forconi; Talha Munir
Journal:  J Clin Oncol       Date:  2019-07-11       Impact factor: 44.544

7.  Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma: Highlights From SOHO 2021.

Authors: 
Journal:  J Adv Pract Oncol       Date:  2022-02-02

8.  Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.

Authors:  Craig A Portell; Nolan A Wages; Brad S Kahl; Lihua E Budde; Robert W Chen; Jonathon B Cohen; Nikole E Varhegyi; Gina R Petroni; Michael E Williams
Journal:  Blood Adv       Date:  2022-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.